PubMed (GeneRIF) for id: 10494

Year	Number of Results
2004	1
2007	1
2008	1
2010	1
2011	1
2012	3
2013	1
2014	1
2015	1
2016	1
2018	1
2019	2
2020	2
2021	1
2022	4
2023	1
2024	0

1

STK25: a viable therapeutic target for cancer treatments?

Chen KQ, Lei GL, Ke BY, Chen L, Wang ZB, Wang SZ. Chen KQ, et al. Anticancer Drugs. 2023 Oct 1;34(9):995-1001. doi: 10.1097/CAD.0000000000001490. Epub 2023 Dec 23. Anticancer Drugs. 2023. PMID: 36728989 Review.

2

STK25 inhibits PKA signaling by phosphorylating PRKAR1A.

Zhang X, Wang BZ, Kim M, Nash TR, Liu B, Rao J, Lock R, Tamargo M, Soni RK, Belov J, Li E, Vunjak-Novakovic G, Fine B. Zhang X, et al. Cell Rep. 2022 Aug 16;40(7):111203. doi: 10.1016/j.celrep.2022.111203. Cell Rep. 2022. PMID: 35977512 Free PMC article.

3

Downregulation of STK25 promotes autophagy via the Janus kinase 2/signal transducer and activator of transcription 3 pathway in colorectal cancer.

Chen J, Gao P, Peng L, Liu T, Wu F, Xu K, Chen L, Tan F, Xing P, Wang Z, Di J, Jiang B, Su X. Chen J, et al. Mol Carcinog. 2022 Jun;61(6):572-586. doi: 10.1002/mc.23403. Epub 2022 Mar 29. Mol Carcinog. 2022. PMID: 35349179

4

Loss of serine/threonine protein kinase 25 in retinal ganglion cells ameliorates high glucose-elicited damage through regulation of the AKT-GSK-3β/Nrf2 pathway.

Zhou Z, Li H, Bai S, Xu Z, Jiao Y. Zhou Z, et al. Biochem Biophys Res Commun. 2022 Apr 16;600:87-93. doi: 10.1016/j.bbrc.2022.02.044. Epub 2022 Feb 12. Biochem Biophys Res Commun. 2022. PMID: 35217361

5

Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.

Kurhe Y, Caputo M, Cansby E, Xia Y, Kumari S, Anand SK, Howell BW, Marschall HU, Mahlapuu M. Kurhe Y, et al. Cell Mol Gastroenterol Hepatol. 2022;13(2):405-423. doi: 10.1016/j.jcmgh.2021.09.018. Epub 2021 Oct 6. Cell Mol Gastroenterol Hepatol. 2022. PMID: 34624527 Free PMC article.

6

Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease.

Cansby E, Caputo M, Gao L, Kulkarni NM, Nerstedt A, Ståhlman M, Borén J, Porosk R, Soomets U, Pedrelli M, Parini P, Marschall HU, Nyström J, Howell BW, Mahlapuu M. Cansby E, et al. JCI Insight. 2020 Dec 17;5(24):e140483. doi: 10.1172/jci.insight.140483. JCI Insight. 2020. PMID: 33170807 Free PMC article.

7

STK25 suppresses Hippo signaling by regulating SAV1-STRIPAK antagonism.

Bae SJ, Ni L, Luo X. Bae SJ, et al. Elife. 2020 Apr 15;9:e54863. doi: 10.7554/eLife.54863. Elife. 2020. PMID: 32292165 Free PMC article.

8

Identification of the kinase STK25 as an upstream activator of LATS signaling.

Lim S, Hermance N, Mudianto T, Mustaly HM, Mauricio IPM, Vittoria MA, Quinton RJ, Howell BW, Cornils H, Manning AL, Ganem NJ. Lim S, et al. Nat Commun. 2019 Apr 4;10(1):1547. doi: 10.1038/s41467-019-09597-w. Nat Commun. 2019. PMID: 30948712 Free PMC article.

9

p21^WAF1/Cip1 Regulation by hYSK1 Activates SP-1 Transcription Factor and Increases MMP-2 Expression under Hypoxic Conditions.

Lee MH, Kundu JK, Choi BY. Lee MH, et al. Int J Mol Sci. 2019 Jan 14;20(2):310. doi: 10.3390/ijms20020310. Int J Mol Sci. 2019. PMID: 30646538 Free PMC article.

10

STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer.

Wu F, Gao P, Wu W, Wang Z, Yang J, Di J, Jiang B, Su X. Wu F, et al. J Exp Clin Cancer Res. 2018 Jul 11;37(1):144. doi: 10.1186/s13046-018-0808-1. J Exp Clin Cancer Res. 2018. PMID: 29996891 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

21 results

Results by year